Case Studies

Case Studies

Case Studies

Microsoft Teams Calling

Jul 4, 2025

MS team calling
MS team calling
MS team calling
MS team calling

How NDA Group Revolutionized Global Pharmaceutical Communications: A Human-First Connectivity Success Story

The Challenge: When Traditional Communication Systems Fail Growing Pharmaceutical Companies

In the fast-evolving pharmaceutical industry, effective communication infrastructure has become a strategic business enabler rather than a simple operational necessity. For NDA Group, a leading regulatory drug and device development consultancy operating across four international offices, their existing Mitel solution using ISDN lines was creating significant barriers to the hybrid working model that modern pharmaceutical work demands.

The pharmaceutical industry's adaptation to hybrid working has been particularly complex due to regulatory requirements and confidential information handling. Studies show that 73% of employees need better reasons to return to full-time office environments, creating unique challenges for pharmaceutical consultancies where regulatory expertise must be available on-demand regardless of physical location.

For NDA Group, with IT headquarters in Sweden and offices throughout Europe, finding a connectivity partner capable of delivering consistent service quality across all territories while maintaining the high-touch support their business-critical operations required represented a significant challenge. Traditional telecommunications providers often struggle with international deployments due to fragmented support structures and limited local expertise in each market.

The Human-First Solution: Why AMVIA Made the Difference

The pharmaceutical industry's emphasis on expert relationships and personal service makes human-first communication providers particularly valuable. When regulatory challenges arise or urgent client needs develop, direct expert access becomes business-critical for companies supporting drug development across multiple jurisdictions.

AMVIA's selection as NDA Group's connectivity partner reflected their unique position in the market as a human-first alternative to tech-first giants. Unlike larger providers who route support through automated systems and multi-tier call centers, AMVIA provides direct access to technical experts through their no-voicemail policy at 0333 733 8050.

This approach proved particularly valuable for NDA Group's international deployment, where time zone differences and complex technical requirements demanded immediate expert attention rather than lengthy support ticket processes. AMVIA's independent provider status with access to over 50 network suppliers enabled optimal service delivery across NDA Group's international footprint.

Microsoft Teams Calling: The Strategic Choice for Pharmaceutical Excellence

The decision to deploy Microsoft Teams Calling addressed NDA Group's core requirement for a unified communication platform that could support their hybrid working model. With teams already using Microsoft Teams for online meetings both internally and with clients, the familiar user interface minimized training requirements and cultural shock during deployment.

Microsoft Teams Calling integration with Microsoft 365 provided additional benefits including seamless Outlook integration, shared calendars, and collaborative document access within the same platform. For a pharmaceutical consultancy managing complex regulatory timelines and multi-jurisdictional submissions, this integration streamlined workflows and improved collaboration efficiency.

The pharmaceutical industry's digital transformation in 2025 has accelerated the adoption of unified communications platforms, with over 280 million users worldwide now using Microsoft Teams. This trend reflects the industry's recognition that modern communication infrastructure supports strategic business outcomes rather than simply replacing traditional telephony.

Implementation Excellence: Navigating International Complexity

AMVIA's human-first approach began with comprehensive stakeholder engagement across all NDA Group offices. Rather than deploying a one-size-fits-all solution, AMVIA worked closely with local teams to understand territory-specific requirements and user preferences.

The pre-switchover communication strategy included customized training materials and change management support tailored to each office's operational context. This approach proved essential for pharmaceutical teams where regulatory compliance and confidential communications create additional training considerations.

International number porting represents one of the most challenging aspects of global telecommunications deployments. AMVIA's expert project management and robust planning ensured that all offices moved on assigned dates without issue, despite the complex regulatory requirements across multiple jurisdictions.

The two-month rollout timeline reflects AMVIA's proven deployment capabilities and strategic partnership approach that prioritizes business continuity over aggressive timelines. For NDA Group's business-critical operations, this measured approach prevented service disruptions during peak regulatory submission periods.

Transformational Results: Measurable Impact on Pharmaceutical Operations

The 30% cost reduction compared to the existing on-premise ISDN solution delivered immediate ROI for NDA Group's international operations. Traditional ISDN channels at £12.75 monthly were replaced with SIP trunks costing approximately £4.95 monthly, generating substantial ongoing savings that enabled NDA Group to reinvest in core regulatory expertise.

The simple system management and administration capabilities enabled all offices to own their solution rather than depending on centralized IT support from Sweden headquarters. This decentralized management approach improved response times for local issues while reducing operational overhead.

The almost complete removal of desktop phones across all offices reflected the successful adoption of mobile-first communications that support hybrid working models. For pharmaceutical consultants who travel frequently to client sites and regulatory meetings, this device flexibility proved immediately valuable.

The Broader Impact: Pharmaceutical Communication Transformation

NDA Group's successful transformation demonstrates that enterprise-grade connectivity requires more than technical specifications—it demands human expertise, proactive partnership, and strategic thinking that larger providers simply cannot deliver.

The pharmaceutical industry's increasing focus on digital transformation has made communication infrastructure a strategic differentiator. Leading pharmaceutical companies are recognizing that modern communication capabilities support business agility, regulatory compliance, and client service excellence in ways that traditional telephony cannot match.

Teams Calling integration with Microsoft 365 enabled seamless transitions between voice calls, video conferences, and collaborative document editing within client engagements. This unified platform approach improved client experience and internal collaboration efficiency across NDA Group's international operations.

Strategic Business Outcomes: Beyond Technology Implementation

The unified communication platform enabled NDA Group consultants to respond more rapidly to client inquiries and regulatory emergencies. With direct expert access to AMVIA support and seamless device switching, consultants could maintain connectivity regardless of location or working arrangements.

This enhanced responsiveness proved particularly valuable in pharmaceutical regulatory work where time-sensitive submissions and regulatory authority communications often require immediate expert attention. AMVIA's 24/7 direct expert access provided immediate resolution for any post-deployment issues across all time zones.

The modern communication infrastructure supports NDA Group's positioning as a forward-thinking regulatory consultancy that leverages technology to enhance service delivery. In competitive pharmaceutical consulting markets, technology capabilities increasingly influence client selection decisions.

Future-Proofing Pharmaceutical Communications

AMVIA's relationships with multiple technology vendors provide early access to emerging solutions including 5G integration and advanced collaboration tools. As pharmaceutical work continues evolving toward digital-first processes, these technology partnerships ensure competitive advantages through superior connectivity.

The pharmaceutical industry's increasing focus on cybersecurity and data protection requires communication providers who understand regulatory requirements and compliance challenges. AMVIA's comprehensive cybersecurity solutions and compliance expertise provide additional value beyond basic connectivity services.

AMVIA's human-first approach transforms connectivity from a commodity service into a strategic business enabler. For pharmaceutical consultancies like NDA Group, this partnership model supports business growth and operational excellence rather than constraining capabilities.

Conclusion: The Human Difference in Pharmaceutical Connectivity

The pharmaceutical industry's digital transformation in 2025 continues accelerating, with over 85% of biopharma executives investing in data, AI, and digital tools to build operational resilience. However, NDA Group's success story demonstrates that technology alone cannot deliver transformational business outcomes—it requires human expertise and strategic partnership.

AMVIA's proven track record with leading pharmaceutical consultancies demonstrates how human-first connectivity enables business success rather than constraining operations. The 30% cost reduction, seamless international deployment, and enhanced operational capabilities achieved through AMVIA's approach prove that independent connectivity partners can deliver superior value for business-critical communications.

In an increasingly connected pharmaceutical industry where regulatory deadlines and client expectations continue rising, the human element in connectivity support becomes a genuine competitive advantage. NDA Group's transformation serves as a compelling example of how modern pharmaceutical companies can leverage human-first connectivity to drive business growth while maintaining operational excellence.

Ready to transform your pharmaceutical communications with human-first connectivity? Contact AMVIA today at 0333 733 8050 for direct access to connectivity experts who understand your industry's unique challenges and deliver personalized solutions that larger providers simply cannot match.

Newsletter

Subscribe for updates

Subscribe to our mailing list to get updated about new features, case studies, deals and discounts. No spam.

Newsletter

Subscribe for updates

Subscribe to our mailing list to get updated about new features, case studies, deals and discounts. No spam.

Newsletter

Subscribe for updates

Subscribe to our mailing list to get updated about new features, case studies, deals and discounts. No spam.

Newsletter

Subscribe for updates

Subscribe to our mailing list to get updated about new features, case studies, deals and discounts. No spam.